Dangerous immune reaction emerges as hidden risk in cell therapy treatments

Researchers have identified a life-threatening immune syndrome occurring in patients receiving cellular therapies—a finding that could reshape safety monitoring protocols across the transplant and CAR-T cell industries. The discovery highlights a critical gap in how hospitals screen for and manage rare but severe immune complications, with implications for clinical practice and regulatory oversight.

Originaltitel: Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome